Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines

BMC Molecular Biology

Volumn 12, Issue , 2011, Pages

  Takaoka, Naohisa ^a   Takayama, Tatsuya ^a   Teratani, Takumi ^b   Sugiyama, Takayuki ^a   Mugiya, Soichi ^a   Ozono, Seiichiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 7; MESSENGER RNA; NUCLEAR FACTOR I; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 6; PROTEIN BRN2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; FABP7 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CARCINOGEN DNA INTERACTION; CELL LINE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL STRAIN HEK293; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79960561263     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-12-31     Document Type: Article

References (43)

1. Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 2010, 28:247-52. 10.1007/s00345-010-0555-1, 20390283.
2. Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851-863. 10.1016/j.eururo.2009.01.003, 19155123.
3. Haunerland NH, Spener F. Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res 2004, 43:328-349. 10.1016/j.plipres.2004.05.001, 15234551.
4. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002, 13:141-147. 10.1097/00041433-200204000-00005, 11891416.
5. Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, Harder A, Ackermann A, Malenica B, Brenner W, Zobawa M, Lottspeich F. Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 2005, 5:2631-2640. 10.1002/pmic.200401264, 15892167.
6. Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 2007, 98:77-82. 10.1111/j.1349-7006.2006.00355.x, 17083565.
7. Teratani T, Domoto T, Kuriki K, Kageyama T, Takayama T, Ishikawa A, Ozono S, Nozawa R. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology 2007, 69:236-240. 10.1016/j.urology.2006.09.060, 17320655.
8. Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?. BMC Cancer 2009, 9:248. 10.1186/1471-2407-9-248, 2732640, 19622156.
9. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005, 102:5814-5819. 10.1073/pnas.0402870102, 556127, 15827123.
10. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H, Takata M, Aburatani H, Hoon DS, Saida T, Kawakami Y. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 2006, 66:4443-4449. 10.1158/0008-5472.CAN-05-2505, 16618771.
11. Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, Nguyen L, Nguyen T, Ye X, Morton DL, Hoon DS. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol 2010, 130:221-229. 10.1038/jid.2009.195, 2845961, 19587692.
12. Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 2006, 6:97. 10.1186/1471-2407-6-97, 1479358, 16623952.
13. Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, Delattre JY, Godbout R, Sanson M. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol 2007, 84:245-248. 10.1007/s11060-007-9377-4, 17415524.
14. Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 2008, 8:276. 10.1186/1471-2407-8-276, 2569959, 18826602.
15. Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, Powe DG, Macmillan RD, Caldas C, Ellis IO, Green AR. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 2010, 121:41-51. 10.1007/s10549-009-0450-x, 19590950.
16. Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G, Su J, Cosgrove JM, Xing L, Zhang M, Li J, Aggarwal BB, Meager A, Gentz R. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res 1997, 57:3084-3091.
17. Bisgrove DA, Monckton EA, Packer M, Godbout R. Regulation of Brain Fatty Acid-binding Protein Expression by Differential Phosphorylation of Nuclear Factor I in Malignant Glioma Cell Lines. J Biol Chem 2000, 275:30668-30676.
18. Brun M, Coles JE, Monckton EA, Glubrecht DD, Bisgrove D, Godbout R. Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines. J Mol Biol 2009, 391:282-300. 10.1016/j.jmb.2009.06.041, 19540848.
19. Sánchez-Font MF, Bosch-Comas A, Gonzàlez-Duarte R, Marfany G. Overexpression of FABP7 in Down syndrome fetal brains is associated with PKNOX1 gene-dosage imbalance. Nucleic Acids Res 2003, 31:2769-2777. 10.1093/nar/gkg396, 156729, 12771203.
20. NCBI FABP7 gene resource. , http://www.ncbi.nlm.nih.gov/gene/2173
21. Tsunoda T, Takagi T. Estimating transcription factor bindability on DNA. Bioinformatics 1999, 15:622-630. 10.1093/bioinformatics/15.7.622, 10487870.
22. Transcription Element Search System. , http://www.cbil.upenn.edu/cgi-bin/tess/tess
23. Gronostajski RM. Roles of the NFI/CTF gene family in transcription and development. Gene 2000, 249:31-45. 10.1016/S0378-1119(00)00140-2, 10831836.
24. Kochevar J. A renal cell carcinoma neoplastic antigen detectable by immunohistochemistry is defined by a murine monoclonal antibody. Cancer 1987, 60:2031-2036.
25. Fogh J, Trempe G. New human tumor cell lines. Human Tumor Cells In Vitro 1975, 115-141. New York: Plenum Press, Fogh J.
26. Williams RD, Elliott AY, Stein N, Fraley EE. In vitro cultivation of human renal cell cancer. II. Characterization of cell lines. In Vitro 1978, 14:779-786. 10.1007/BF02617972, 721102.
27. Tölle A, Krause H, Miller K, Jung K, Stephan C. Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. Oncol Rep 2011, 25:1307-1312.
28. Munshi A, Shafi G, Aliya N, Jyothy A. Histone modifications dictate specific biological readouts. J Genet Genomics 2009, 36:75-88. 10.1016/S1673-8527(08)60094-6, 19232306.
29. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002, 99:3740-3745. 10.1073/pnas.052410099, 122594, 11891299.
30. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 19167326.
31. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007, 43:1529-1544. 10.1016/j.ejca.2007.04.002, 17531469.
32. Nakai S, Kawano H, Yudate T, Nishi M, Kuno J, Nagata A, Jishage K, Hamada H, Fujii H, Kawamura K, Shiba K, Noda T. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev 1995, 9:3109-3121. 10.1101/gad.9.24.3109, 8543155.
33. Schonemann MD, Ryan AK, McEvilly RJ, O'Connell SM, Arias CA, Kalla KA, Li P, Sawchenko PE, Rosenfeld MG. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev 1995, 9:3122-3135. 10.1101/gad.9.24.3122, 8543156.
34. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041. 10.1038/nature08797, 2829121, 20107439.
35. Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 2008, 21:611-626. 10.1111/j.1755-148X.2008.00510.x, 18983536.
36. Shi G, Sohn KC, Choi DK, Kim YJ, Kim SJ, Ou BS, Piao YJ, Lee YH, Yoon TJ, Lee Y, Seo YJ, Kim CD, Lee JH. Brn2 is a transcription factor regulating keratinocyte differentiation with a possible role in the pathogenesis of lichen planus. PLoS One 2010, 5:e13216. 10.1371/journal.pone.0013216, 2953493, 20967260.
37. Zwilling S, König H, Wirth T. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J 1995, 14:1198-1208. 398197, 7720710.
38. Tomilin A, Reményi A, Lins K, Bak H, Leidel S, Vriend G, Wilmanns M, Schöler HR. Synergism with the coactivator OBF-1 (OCA-B, BOB-1) is mediated by a specific POU dimer configuration. Cell 2000, 103:853-864. 10.1016/S0092-8674(00)00189-6, 11136971.
39. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol 2007, 8:47. 10.1186/1471-2199-8-47, 1913536, 17559644.
40. Faus I, Hsu HJ, Fuchs E. Oct-6: a regulator of keratinocyte gene expression in stratified squamous epithelia. Mol Cell Biol 1994, 14:3263-3275. 358693, 7909356.
41. Takaoka N, Fukuzawa M, Saito T, Sakaitani T, Ochiai H. Promoter analysis of the membrane protein gp64 gene of the cellular slime mold Polysphondylium pallidum. Biochim Biophys Acta 1999, 1447:226-230.
42. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, Sturm RA, Larue L, Goding CR. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 2008, 68:7788-7794. 10.1158/0008-5472.CAN-08-1053, 18829533.
43. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008, 3:e2734. 10.1371/journal.pone.0002734, 2444043, 18628967.